NU SKIN ENTERPRISES, INC.(NUS)— Stock Profile, AI Score & Financials
Consumer Staples · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
NU SKIN ENTERPRISES, INC. (NUS) stock profile, AI quality score, and SEC EDGAR financial data, a Consumer Staples sector company. 13F Pro's AI-powered ranking engine scores NUS at 22.9/100 on a 32-signal composite quality model, placing it at rank #2,740 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (5.7) and balance sheet strength (12.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 44.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), NU SKIN ENTERPRISES, INC. reports quarterly revenue of $320.1M, net income of $-249.8M, free cash flow of $5.0M. Top institutional holders of NUS by reported 13-F value include BlackRock, AMERICAN CENTURY COMPANIES, Coppell Advisory Solutions, based on the most recent SEC filings. NUS trades on the NYSE exchange and files with the SEC under CIK 1021561. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NUS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NU SKIN ENTERPRISES, INC. directly from SEC EDGAR.
AI Quality Score
22.9/100
AI Rank
#2,740
Revenue
$320.1M
Net Income
$-249.8M
Free Cash Flow
$5.0M
NUS key financials by period
NU SKIN ENTERPRISES, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$1.5B
$160.2M
4.4%
FY 2024
10-K
$1.7B
$-146.6M
-8.8%
FY 2023
10-K
$2.0B
$8.6M
2.5%
FY 2022
10-K
$2.2B
$104.8M
5.0%
FY 2021
10-K
$2.7B
$147.3M
8.7%
FY 2020
10-K
$2.6B
$191.4M
10.0%
Institutions holding NUS
Institutional investors reporting a position in NU SKIN ENTERPRISES, INC. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-10 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Revenue fell 17.1% YoY to $320.1M, driven by macroeconomic headwinds across all geographies; $78.9M goodwill impairment and $167.5M tax valuation allowance led to $(249.8)M net loss.
Biggest Revenue Drivers
Nu Skin Americas$59.8M-18.1% YoY
Continued decline in North America markets; switching costs from Prysm iO adoption; negative FX impact of 2.3%.
Rhyz Manufacturing$46.4M-23.2% YoY
Challenging comparison with strong prior year; customer order delays from tariff and economic uncertainty.
Biggest Revenue Drivers
Total revenue: $320.1M-17.1% YoY
Nu Skin Americas$59.8M-18.1% YoY
Continued decline in North America markets; switching costs from Prysm iO adoption; negative FX impact of 2.3%.
Rhyz Manufacturing$46.4M-23.2% YoY
Challenging comparison with strong prior year; customer order delays from tariff and economic uncertainty.
Mainland China$46.0M-13.7% YoY
Continued macroeconomic challenges; shift of consumer demand to online marketplaces; offset by 5.0% favorable FX.
Southeast Asia/Pacific$43.3M-14.9% YoY
Slowing momentum from general macroeconomic factors; pre-market activities in India; 1.4% favorable FX benefit.
Japan$38.1M-14.4% YoY
Consumer inflationary pressures depressing spending; offset partially by 8.8% negative FX impact.
Largest Expense Items
Impairment expenses$78.9Mvs. $0M prior year
Goodwill impairment on Manufacturing reporting unit due to stock price decline and manufacturing forecast deterioration.
Provision for income taxes$186.6Mvs. $6.3M prior year
$167.5M valuation allowance on U.S. deferred tax assets due to cumulative losses over past three years.
Selling expenses$107.9Mvs. $128.2M prior year
Higher selling expense percentage from sales compensation plan enhancements and Prysm iO transition incentives.
General and administrative expenses$90.8Mvs. $106.7M prior year
$8.6M labor expense reduction from lower incentive compensation; $2.5M software contract savings from cost management.
Margins: Gross margin as percentage of revenue decreased to 68.2% (from 68.8% prior year) due to Manufacturing segment pressure, though core Nu Skin gross margin improved 0.2 percentage points. Operating margin deteriorated sharply to negative 18.5% from positive 8.0%, driven primarily by the $78.9M goodwill impairment charge.
Watch Items from the Filing
$167.5M valuation allowance established on U.S. deferred tax assets in Q2 2026; cumulative U.S. losses over past three years deemed more likely than not to be unrealizable.
Operating loss of $(59.3)M in Q2 2026 vs. operating income of $30.8M in prior year; segment contribution declined 28% YoY to $60.0M.
Customers, Paid Affiliates, and Sales Leaders all declined 14%, 8%, and 9% YoY respectively; continued macroeconomic headwinds and consumer spending weakness across all major markets.
Manufacturing segment recorded $(0.6)M segment contribution vs. $3.7M prior year; includes $78.9M goodwill impairment reflecting significant asset value deterioration.
India pre-market launch delayed from 2026 to first half 2027; company identified need to simplify operating model; expenses incurred for preparation included in Southeast Asia/Pacific segment.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
